175% Stock Surge: Two Major Biotech Companies Form This Partnership

AstraZeneca and Cellectis: A Strategic Collaboration Set to Revolutionize Biotech.

Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

In a remarkable turn of events, Cellectis' stock (NASDAQ: $CLLS) has surged by an impressive 175% in premarket trading, reaching a new high of $2.69. This surprising trend follows a significant announcement ma…